NextCure (NASDAQ:NXTC) PT Raised to $33.00 at Morgan Stanley
NextCure (NASDAQ:NXTC) had its target price raised by Morgan Stanley from $25.00 to $33.00 in a research report sent to investors on Tuesday, AnalystRatings.com reports. Morgan Stanley currently has an overweight rating on the stock.
A number of other research analysts have also recently weighed in on NXTC. Bank of America initiated coverage on shares of NextCure in a report on Tuesday, July 9th. They issued a buy rating and a $25.00 price objective for the company. Piper Jaffray Companies initiated coverage on shares of NextCure in a report on Monday, June 3rd. They issued an overweight rating and a $26.00 price objective for the company.
Shares of NextCure stock opened at $26.71 on Tuesday. The business’s fifty day simple moving average is $18.87. NextCure has a 1 year low of $13.86 and a 1 year high of $27.89.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC purchased a new position in NextCure in the second quarter valued at $96,000. Northern Trust Corp purchased a new stake in shares of NextCure during the second quarter worth about $337,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of NextCure during the second quarter worth about $386,000. Indus Capital Partners LLC purchased a new stake in shares of NextCure during the second quarter worth about $1,407,000. Finally, Yale University purchased a new stake in shares of NextCure during the second quarter worth about $1,865,000. 2.06% of the stock is owned by institutional investors.
NextCure Company Profile
There is no company description available for NextCure Inc
Featured Article: How Do You Make Money With Penny Stocks?
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.